Fifty patients fulfilling operational criteria for the chronic fatigue syndrome (CFS), and who had been ill for a mean of five years, were offered cognitive behaviour therapy in an open trial. Those fulfilling operational criteria for depressive illness were also offered tricyclic antidepressants. The rationale was that a distinction be drawn between factors that precipitate the illness and those that perpetuate it. Among the latter are cognitive factors such as the belief that physical symptoms always imply tissue damage, and behavioural factors such as persistent avoidance of activities associated with an increase in symptoms. Therapy led to substantial improvements in overall disability, fatigue, somatic and psychiatric symptoms. The principal problems encountered were a high refusal rate and difficulties in treating affective disorders. Outcome depended more on the strength of the initial attribution of symptoms to exclusively physical causes, and was not influenced by length of illness. These results suggest that current views on both treatment and prognosis in CFS are unnecessarily pessimistic. It is also suggested that advice currently offered to chronic patients, to avoid physical and mental activity, is counterproductive.
The chronic fatigue syndrome, also known as postviral fatigue or myalgic encephalomyelitis, continues to attract attention and controversy. The scale of the problem is unknown, largely due to difficulties in case definition,' but it seems probable that increasing numbers of people are being diagnosed, or diagnosing themselves, as suffering from the condition. At the beginning of 1989 over 150 people a week were joining the principal patients' organisation.'
Even nomenclature remains a problem in this field. Myalgic encephalomyelitis (ME) is frequently encountered, but is unsatisfactory for many reasons.3 Postviral fatigue syndrome implies an aetiology that is by no means certain. For the rest of this paper we have followed the international consensus of using the term "chronic fatigue syndrome" (CFS), as it is short, accurate and has no aetiological implications.4
The cause of CFS remains unknown.
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Various factors, both medical and psychiatric, have been implicated.3 At present, however, evidence has only been presented from small, selected case control studies.' Furthermore, such studies are only able to report associations, not aetiologies, and may not apply to the majority of patients with the clinical syndrome.35 There are also no established treatments for CFS. Suggested methods of management that focus on presumed chronic infection have so far been found wanting.67
Instead, most patients receive very little in the way of practical help. The mainstay of treatment remains rest, and to wait either for remission or a medical cure, and the advice consistently offered by the current self help groups is to avoid physical and mental activity. Others are told to accept disability as "living within their limits". This state of affairs has been succinctly described as "therapeutic nihilism"8 and is unsatisfactory.
What little we know about the natural history of these conditions9 shows that untreated they can be severe and persistent. In the largest current series "Most of the cases seen do not improve, give up their work and become permanent invalids". 43 (86%) complained of post exercise myalgia. Over 50% of the sample also complained of the following symptoms: nausea, dizziness, daytime drowsiness, back pain, headaches, tremor, perspiration, eyestrain, paraesthesiae and insomnia. Three quarters (76%) reported that their illness had begun after a "viral" infection, and 42/50 (84%) believed they had postviral fatigue syndrome or "ME." Twenty seven (54%) were members of the ME Association. Most had made their own diagnosis or had been diagnosed by a doctor specialising in "ME".
All patients fulfilling the criteria were referred by the neurological staff as part of a previous study into the nature of fatigue in the postviral syndrome. After completing self report questionnaires and a standardised interview'9 all were given a brief description of treatment by the psychiatrists. Those who fulfilled operational criteria for depression were also started on antidepressant medication (see later). A further assessment took place between four to six weeks later, and was carried out by the two therapists. After further discussion an offer of treatment was made, and therapy started on the next visit.
Thirty two patients accepted the offer of treatment, of whom 26 were treated as outpatients. The mean therapist time was 7-5 hours, with a range from two to 20 hours of treatment. Six had such severe disability (being confined to bed or a wheelchair for most or all ofthe time), that it was necessary to admit them to hospital for a period ofbetween three to eight weeks.
Treatment followed cognitive behavioural principles,3' derived from work on the management of chronic pain,27 but adapted for the particular problems of CFS. Full details and techniques are reported elsewhere,'7 but a brief account follows. After a detailed assessment, patient and therapist identified prominent disabilities, and looked at the associations and reasons advanced for such disabilities. Cognitive distortions, when present, were noted, and patients were encouraged to look for alternative explanations. Self monitoring of both behaviour and cognitions was also encouraged. Behavioural targets were jointly agreed upon, based on avoided activities which the patient wished to resume. These were practised between sessions. The intention was to introduce predictability into the pattern of rest and activity, and to encourage self efficacy-this was phrased as "helping the patient, and not 'ME', to be in control". Later in treatment the patient was encouraged to break the association between symptoms and ceasing activity, so that sensitisation to symptoms and activity was replaced by tolerance.
Twenty patients were offered tricyclic antidepressants at the initial psychiatric interview. Dothiepin, a conventional tricyclic antidepressant, was prescribed in doses ranging from 75 to 150 mg, depending upon ability to tolerate side effects. All fulfilled the Research Diagnostic Criteria' for probable or definite major depression. Three of those offered treatment declined. Similar treatment was also given to an additional three patients who fulfilled criteria for other psychiatric disorders (two somatisation, one anxiety), and were already receiving antidepressants. Those given antidepressants scored higher on scales measuring psychiatric symptoms, somatic symptoms, and mental fatigue, and were more functionally impaired. However, there were no differences in the length of illness, nor physical fatigue, which is consistent with previous observations on this sample. '9 After four to six weeks all patients were seen by the behaviour therapists, at which time mood disorder was reassessed with the Beck Depression Inventory (BDI).29 There were no longer differences in the severity of mood disorder between those who had been prescribed antidepressants and those who had not (mean Beck Depression Score for those receiving antidepressants was 10 2 (6-7-13 8), compared with 8-8 (4-1-13-5), although they still had significantly higher numbers of somatic (table 3) . Of those who completed treatment, there was an overall self rated percentage improvement in disability of 60% (95% confidence interval 41-78%). In most, improvement occurred globally. The decline in functional disability correlated with a decrease in mood and anxiety related symptoms and also somatic symptoms (data not shown). Some experienced a greater than 50% improvement in symptoms and disability, but remained symptomatic, especially with a variety of somatic discomforts. In only three patients was there greater than a 50% decrease in psychiatric symptomatology without an equivalent improvement in functional impairment.
Twenty three (70% of those starting therapy) patients described themselves as "better" or "much better". Stricter criteria, however, were used to determine complete recovery. These were as follows: below threshold scores on all of the GHQ, HAD and BDI measures; a score of 0 or 1 on both the physical fatigue scale (range 0-16) and the mental fatigue scale (Range 0-10), a global score of 1 ("much better"), and a functional disability score of 8 or below (range 0-32). Nine patients met all these requirements (28%).
Eighteen patients (36%) declined the offer of treatment (11 when interviewed by the psychiatrist, seven by the behaviour therapist).
This contrasts with only 5/50 refusals among the last 50 patients referred by neurologists for cognitive behaviour therapy for conditions other than CFS. Length of illness, presence of muscle pain, severity of mental or physical fatigue, history of "viral" illness, current psychiatric illness (RDC criteria) and functional impairment were not associated with the decision to accept or reject treatment. There was a trend for those refusing to be female (15/34 females refused compared to 3/16 males; Chi squared = 2-03; p = 0-15). There was also a trend for refusers to have lower scores on the GHQ-12 (mean GHQ score for refusers = 5.37 (3 39-7-35), accepted = 7.59 (6-27-8 9) , t = 1 83, df = 46, p = 0 078). Although this did not reach conventional statistical significance, this may have been due to lack of power, since a similar non significant trend was observed for HAD scores. Attribution of symptoms also played a role. rhere was a trend for those refusing treatment to be more likely to believe their illness was entirely due to physical factors (Chi squared = 4 61, df = 2, p = 0-09).
Five patients withdrew after starting the programme. Two had already been unable to treatment Beck Depression Score in the good outcome group was 8-25 (5-6-10-9), compared with 11-66 (5-1-18 2) in the poor outcome group; Mean HAD scores were 17-61 (13 2-22 0) compared with 1611 (10-0-22-2)).
However, 3/3 patients who deteriorated were cases of affective disorder, as were 4/6 of those unchanged. The second variable associated with a poor outcome was the strength of attribution to a physical cause ( The nine remaining patients who agreed to treatment did not fulfil the criteria for major depression, and received no antidepressants; 7/9 (77%) had a good outcome.
All patients who successfully completed therapy have now been followed up for three months, as have 3/9 with poor outcomes. Of the nine patients who finished symptom free, eight remain so. One has re-experienced some symptoms, but remains able to work. Most of the remainder are stable, and have maintained their improvement (four have continued to improve further of whom one is now symptom free). Three have experienced a gradual worsening of symptoms, but without any change in functional disability (two were associated with discontinuing antidepressants). In conclusion, at three months follow up the 23 who improved during the treatment all remain better than before.
Discussion
We report an uncontrolled pilot study of treatment of the chronic fatigue syndrome. The management of these patients followed our standard clinical management. The study is thus subject to all the deficiencies of a non blind, non randomised study. In the current climate ofopinion, however, these results are of interest for several reasons.
First, we have shown that something can be done for patients suffering from CFS and related syndromes. Most of those entering the trial experienced an improvement in symptoms and functional activity, and many were able to resume their occupations, or if not employed, experienced a return to previous levels of functioning.
Second, this study suggests that the view that little can be done for patients with CFS is inaccurate. In particular, we have shown that even those experiencing longer than two years of illness, and severe and persistent disability, can still return to premorbid functioning.
Third, the advice customarily given to those with illnesses of long duration, to avoid physical and mental activity, may not only be unnecessary, but sometimes inadvertently counterproductive. Much of the current self help literature and media reporting state that the approach we favour should lead to persistent illness and increased morbidity, especially in those with chronic disability.
Overall, only three out of 32 patients were worse after entering the trial. All had mood disorder on entry, which persisted throughout treatment. Two of the three were unable to tolerate conventional therapy in the form of antidepressants. A major reason for a lack of improvement was therefore persistent mood disorder. It is possible that others who would have suffered adverse effects declined the offer of treatment, and such fears were indeed the principal reason expressed for refusal. The accuracy of that perception is impossible to determine, but there were few clinical or symptomatic factors associated with refusal. Instead, the trend for those refusing treatment are more likely to attribute all their symptoms to a purely physical problem, and less likely to accept an interaction between physical and psychological, may reflect the external social pressures that complicate so much of CFS. 34 Both persistent mood disorder and the strength ofattributions ofillness contributed to poor outcome. More Demonstrating the benefits of cognitive behaviour therapy sheds little light on the nature of the initial pathology in CFS. The balance between physical, psychological and social factors changes over time in many illnesses. Our results are compatible with current theories on either a viral or immune precipitant. Such factors are not, however, the only cause of long term disability. Even if all cases of CFS are initially the result of viral infection, which seems unlikely,' the secondary consequences, both social and psychological, may be a more potent cause of long term disability, analogous to the long term outcome of chronic pain2 22 and head injury.'9 Fortunately, such secondary factors are more amenable to treatment at present.
Details of the clinical characteristics of the patients confirm that the current sample was typical of hospital samples currently viewed as having severe postviral fatigue/"ME", and resembled those reported from other specialised referral centres. All fulfilled recent consensus criteria for CFS.'4 Our findings can therefore be generalised to other CFS patients seen in hospital practice with severe fatigue of long duration and a diagnois ofpostviral fatigue syndrome or its equivalent. The results, however, cannot be assumed to apply to those seen in general practice, or with shorter durations of illness.
Future trials are essential to clarify these results. In particular, randomisation ofpatients to either the above therapy, rest or antidepressants is necessary. Other improvements, including independent ratings, should be used, although any trial of this nature will ultimately depend upon self report. Finally, it is hoped that the current unwelcome "polarisation of attitudes"'" concerning the nature of CFS will change, to allow empirical treatments, as outlined in this paper, to become more widely available than at present.
In conclusion, these results confirm the intuition of Jerome Frank,4' who wrote that "Patients suffering from unfamiliar diseases tend to develop emotional reactions which impede recovery, such as anxiety, resentment and confusion. To keep disability at a minimum, therapeutic efforts must be directed not only to overcoming the pathogenic agent but to maintaining the patient's confidence in the physician, and encouraging his'expectation of a return to useful activity".
